Molecule Details
| InChIKey | DWPQODZAOSWNHB-UHFFFAOYSA-N |
|---|---|
| Compound Name | 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4H-imidazol-2-yl)urea |
| Canonical SMILES | CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 7.25 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12931 |
|---|---|
| Drug Name | Fenobam |
| CAS Number | 57653-26-6 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome). |
Cross-references: BindingDB: 50105838 ChEBI: 92728 CHEMBL239800 ChemSpider: 142953 PDB: D7W PubChem:162834 PubChem:347829076 Wikipedia: Fenobam ZINC: ZINC000000001436
Target Activities (3)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P41594 | GRM5 | Metabotropic glutamate receptor 5 | allosteric modulator | targets |